Pub Date : 2022-01-07DOI: 10.19080/ctoij.2022.20.556040
Welington Lombardi
{"title":"Liver Metastasis as the First Manifestation of Occult Breast Carcinoma","authors":"Welington Lombardi","doi":"10.19080/ctoij.2022.20.556040","DOIUrl":"https://doi.org/10.19080/ctoij.2022.20.556040","url":null,"abstract":"","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115266306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-04DOI: 10.19080/ctoij.2022.20.556039
A. Mohanty
{"title":"Osteoclastoma-Like Giant Cell Tumour of the Liver – First Reported Case from Kuwait","authors":"A. Mohanty","doi":"10.19080/ctoij.2022.20.556039","DOIUrl":"https://doi.org/10.19080/ctoij.2022.20.556039","url":null,"abstract":"","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"181 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121587492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-27DOI: 10.19080/ctoij.2021.20.556038
M. Mazhar
A group of diseases that originate from the different parts of ovaries and cause production of abnormal cells that divide uncontrolled themselves in the ovaries is known as ovarian cancer. OC is mainly classified into majorly three types on the base of three components of ovaries known as epithelium, stroma and germinal cells. Approximately, 7000 women develop OC and 4200 of them die every year in the UK. In Pakistan, the incidence of OC is increasing at the rate of around 13.6%. Approximately 70% cases are diagnosed at later stages. The blood sample was collected in the Layyah region. The CA125 identification through Elisa technique for their better identification on the basis of antibodies. Normal values of CA125 were considered less than 35 U/ml. The other tumor markers were also measured such as fibrinogen, prolactin, CA15.3, PT, APTT, INR, D Dimer, and CA19.9. The mean age of patients was 59.0 ± 8.1while the minimum and maximum age at which the tumor marker detection was 22 and 74 years. The number of patients was found in order of 25 >24 > 10 in 1st,2nd and 3rd age groups, respectively. The clinical histopathological test in the ovarian cancer patients show that the tumor size 5.21±3.42, fibrinogen 5.09±1.29, CA-199 (U/mL) 121.17±59.76, and D-dimer 0.61±0.31. The CA-125 level increase in ovarian cancer patients is indicated as a tumor marker.
{"title":"Prevalence of Ovarian Cancer and Its Correlation with Age in Pakistan","authors":"M. Mazhar","doi":"10.19080/ctoij.2021.20.556038","DOIUrl":"https://doi.org/10.19080/ctoij.2021.20.556038","url":null,"abstract":"A group of diseases that originate from the different parts of ovaries and cause production of abnormal cells that divide uncontrolled themselves in the ovaries is known as ovarian cancer. OC is mainly classified into majorly three types on the base of three components of ovaries known as epithelium, stroma and germinal cells. Approximately, 7000 women develop OC and 4200 of them die every year in the UK. In Pakistan, the incidence of OC is increasing at the rate of around 13.6%. Approximately 70% cases are diagnosed at later stages. The blood sample was collected in the Layyah region. The CA125 identification through Elisa technique for their better identification on the basis of antibodies. Normal values of CA125 were considered less than 35 U/ml. The other tumor markers were also measured such as fibrinogen, prolactin, CA15.3, PT, APTT, INR, D Dimer, and CA19.9. The mean age of patients was 59.0 ± 8.1while the minimum and maximum age at which the tumor marker detection was 22 and 74 years. The number of patients was found in order of 25 >24 > 10 in 1st,2nd and 3rd age groups, respectively. The clinical histopathological test in the ovarian cancer patients show that the tumor size 5.21±3.42, fibrinogen 5.09±1.29, CA-199 (U/mL) 121.17±59.76, and D-dimer 0.61±0.31. The CA-125 level increase in ovarian cancer patients is indicated as a tumor marker.","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130255231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.19080/ctoij.2021.20.556037
M. Tan
Cancer is one of the top causes of death, and a huge barrier for high-quality life globally [1]. In 2020 alone, there were 19.3 million new cases, of which close to 10 million were fatal [2]. It is estimated that cancer-related healthcare costs would amount to $232.9 billion between 2020 and 2030 [3]. Therefore, it is imperative to develop new and improved medicines for cancer therapy to enhance the patients’ quality of life lower the mortality rates. Currently, an increasing number of prospective medicines and novel therapies are being tested in clinical trials, some of which have benefited the enrolled patients. Here, we will review the eve and challenges of cancer therapy, with particular focus on immunotherapy and targeted therapy.
{"title":"New Horizons and Challenges of Cancer Therapy","authors":"M. Tan","doi":"10.19080/ctoij.2021.20.556037","DOIUrl":"https://doi.org/10.19080/ctoij.2021.20.556037","url":null,"abstract":"Cancer is one of the top causes of death, and a huge barrier for high-quality life globally [1]. In 2020 alone, there were 19.3 million new cases, of which close to 10 million were fatal [2]. It is estimated that cancer-related healthcare costs would amount to $232.9 billion between 2020 and 2030 [3]. Therefore, it is imperative to develop new and improved medicines for cancer therapy to enhance the patients’ quality of life lower the mortality rates. Currently, an increasing number of prospective medicines and novel therapies are being tested in clinical trials, some of which have benefited the enrolled patients. Here, we will review the eve and challenges of cancer therapy, with particular focus on immunotherapy and targeted therapy.","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126828748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-10DOI: 10.19080/ctoij.2021.20.556036
Sakhri Selma
{"title":"Cancer and Virtual Reality VR, the Great Challenge of the Century","authors":"Sakhri Selma","doi":"10.19080/ctoij.2021.20.556036","DOIUrl":"https://doi.org/10.19080/ctoij.2021.20.556036","url":null,"abstract":"","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132754683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-07DOI: 10.19080/ctoij.2021.20.556035
N. Hamed
{"title":"COVID-19 and Cytokine Storm","authors":"N. Hamed","doi":"10.19080/ctoij.2021.20.556035","DOIUrl":"https://doi.org/10.19080/ctoij.2021.20.556035","url":null,"abstract":"","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115620238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-12DOI: 10.19080/ctoij.2021.20.556032
Martín González
{"title":"Atypical Fibroxanthoma of the Eyelid - Surgical Resolution and Unexpected Complication, a Case Report","authors":"Martín González","doi":"10.19080/ctoij.2021.20.556032","DOIUrl":"https://doi.org/10.19080/ctoij.2021.20.556032","url":null,"abstract":"","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"238 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131668222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-08DOI: 10.19080/ctoij.2021.20.556031
N. Nouri
{"title":"Comparison of three Diagnostic Methods of Real time PCR, Reverse Dot Blot and DNA Sequencing for Analysis of KRAS Mutations in Patients with Colorectal Cancer","authors":"N. Nouri","doi":"10.19080/ctoij.2021.20.556031","DOIUrl":"https://doi.org/10.19080/ctoij.2021.20.556031","url":null,"abstract":"","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131567503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-27DOI: 10.19080/ctoij.2021.20.556029
Jiewen Guo
{"title":"Strychnine, a Natural Alkaloid, induces Liver Cancer cells Apoptosis and G0/G1-Phase Arrest through IL-6/JAK2/Stat3 Signaling Pathway","authors":"Jiewen Guo","doi":"10.19080/ctoij.2021.20.556029","DOIUrl":"https://doi.org/10.19080/ctoij.2021.20.556029","url":null,"abstract":"","PeriodicalId":360247,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126099183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：